At least four biotechs reported earnings last week. Myriad Genetics Inc. (NASDAQ:MYGN), which markets cancer diagnostics including BRACAnalysis for breast cancer, fell 9% despite beating the Street's revenue and earnings estimates. The stock faltered following a downgrade by Cowen to Market Perform from Outperform (see Analyst Picks, A18). Canadian specialty pharma Paladin Labs Inc. (TSX:PLB) gained 6% after beating the Street's EPS estimate. (A) Fiscal 4Q; Mcap in $M

2Q13

2Q13

Growth

 EPS

 EPS

from

8/16

Wk

%

Mcap

8/16